Literature DB >> 2450341

Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands.

P A Abrahamsson1, H Lilja, S Falkmer, L B Wadström.   

Abstract

Prostatic acid phosphate (PAP), prostate-specific antigen (PSA), and beta-microseminoprotein (beta-MSP) were regularly localized immunohistochemically to the epithelium of the acini and that of the ducts in the nodules of 24 cases of benign prostatic hyperplasia. The immunohistochemical distribution of these three prostatic-secreted proteins was also examined, with monoclonal antisera against PAP and PSA and with polyclonal antisera against PAP, PSA, and beta-MSP, in a series of 40 cases of prostatic adenocarcinomas graded according to the WHO classification. Highly differentiated (grade I) carcinomas showed a high incidence of PAP-, PSA-, and beta-MSP-immunoreactive cells. As in the normal and hyperplastic prostate parenchyma, highly differentiated (grade I) carcinomas were found to contain an almost equal number of PAP-, PSA-, and beta-MSP-immunoreactive cells. When semiquantitatively assessed, the incidence of PAP-, PSA-, and beta-MSP-immunoreactive cells was found to be lower in the moderately and poorly differentiated (grades II and III) tumors than in the highly differentiated ones; they also showed greater staining variability. Tumor cells immunoreactive with a monoclonal antiserum raised against PAP in carcinomas of grades II and III were less frequent than tumor cells immunoreactive with antisera against PSA, beta-MSP, and a polyclonal antiserum against PAP. The almost identical distribution of PSA and beta-MSP in carcinomas of grades II and III suggests that PSA and beta-MSP are not less sensitive tumor markers than PAP for the monitoring of the course and the treatment of prostatic carcinomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450341     DOI: 10.1002/pros.2990120106

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  30 in total

1.  Application of Gleason analogous grading system and flow cytometry DNA analysis in a novel knock-in mouse prostate cancer model.

Authors:  G Wu; Lei Yu; L Wang; H Wang; J W Xuan
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

2.  Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors.

Authors:  R R Tremblay; D Deperthes; B Têtu; J Y Dubé
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

3.  The evaluation of markers of prostatic function.

Authors:  H von der Kammer; K H Scheit; W Weidner; T G Cooper
Journal:  Urol Res       Date:  1991

4.  Replacement of the Disulfide Bridge in a KLK3-Stimulating Peptide Using Orthogonally Protected Building Blocks.

Authors:  Kristian Meinander; Miikka Pakkala; Janne Weisell; Ulf-Håkan Stenman; Hannu Koistinen; Ale Närvänen; Erik A A Wallén
Journal:  ACS Med Chem Lett       Date:  2013-12-16       Impact factor: 4.345

5.  Beta microseminoprotein is not a prostate-specific protein. Its identification in mucous glands and secretions.

Authors:  H Weiber; C Andersson; A Murne; G Rannevik; C Lindström; H Lilja; P Fernlund
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

6.  Characterization of ostrich (Struthio camelus) beta-microseminoprotein (MSP): identification of homologous sequences in EST databases and analysis of their evolution during speciation.

Authors:  C Lazure; M Villemure; D Gauthier; R J Naudé; M Mbikay
Journal:  Protein Sci       Date:  2001-11       Impact factor: 6.725

7.  Total protein and acid phosphatase concentrations in prostatic fluid from patients with BPH compared to carcinoma.

Authors:  E D Kim; N D Smith; J T Grayhack
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

8.  The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor.

Authors:  H von der Kammer; C Jurincic-Winkler; R Horlbeck; K F Klippel; H U Pixberg; K H Scheit
Journal:  Urol Res       Date:  1993-05

9.  Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations.

Authors:  Christopher A Haiman; Daniel O Stram; Andrew J Vickers; Lynne R Wilkens; Katharina Braun; Camilla Valtonen-André; Mari Peltola; Kim Pettersson; Kevin M Waters; Loic Le Marchand; Laurence N Kolonel; Brian E Henderson; Hans Lilja
Journal:  J Natl Cancer Inst       Date:  2012-12-03       Impact factor: 13.506

10.  A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.

Authors:  Primo N Lara; Jeff Longmate; Christopher P Evans; David I Quinn; Przemyslaw Twardowski; Gurkamal Chatta; Edwin Posadas; Walter Stadler; David R Gandara
Journal:  Anticancer Drugs       Date:  2009-03       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.